Skip to content
value.today

IRulya Therapeutics Inc.

IRLA
$343 Mmarket cap on Oct 30, 2026
Compare
World rank
#14,231
Revenue
—
For year ending December-2025
Net income
$-84 M
SEC filing
Employees
55
As on 2021
value.today research

IRulya Therapeutics Inc. in brief

IRulya Therapeutics Inc. is a listed company in the Biotechnology industry, based in California, USA. Its market value was $343 M on 30 October 2026, which makes it the 14,231st largest listed company in the world and the 2,786th largest in the USA on this site. It employs about 55 people. Its shares trade under the symbol IRLA (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About IRulya Therapeutics Inc.

Cortexyme is a Clinical Stage Biopharmaceutical company. It is a pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed and other degenerative diseases. The company is targeting a specific, infectious pathogen found in the brain of Alzheimer’s patients that causes neurodegeneration and other pathology in animal models. The headquarters is in USA.

IRulya Therapeutics Inc. timeline

4 events, 2016–2026
  1. 2016
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2019
  4. 🔔
    Initial public offering as Cortexyme, Inc.
    Final prospectus filed with the SEC on 9 May 2019; shares registered for exchange trading on 1 May 2019.
  5. 2022
  6. ✎
    Renamed Quince Therapeutics, Inc.
    Formerly Cortexyme, Inc..
  7. 2026
  8. ✎
    Renamed IRulya Therapeutics Inc.
    Formerly Quince Therapeutics, Inc..

Events of IRulya Therapeutics Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$399 M$798 M$1.2 B$1.6 B2020202120222023202420252026

World rank over time

▼ down 8,133 places since 2020
2020-01-01: #6127#6,12720202021-01-01: #8795#8,79520212022-01-07: #15475#15,47520222026-10-14: #14831#14,83120262026-10-30: #14260#14,2602026

Rank in USA: #1,776 (Jan 2020) · #2,361 (Jan 2021) · #3,262 (Jan 2022) · #2,873 (Oct 2026) · #2,790 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
-12.2%
Net margin
—
Operating margin
—
Return on equity
—
Liabilities / assets
138.2%
Net debt
$-6M
Profit per employee
$-1.5 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-12M—FY18Fiscal year ending Dec 2019: revenue —, net income $-37M—FY19Fiscal year ending Dec 2020: revenue —, net income $-77M—FY20Fiscal year ending Dec 2021: revenue —, net income $-90M—FY21Fiscal year ending Dec 2022: revenue —, net income $-52M—FY22Fiscal year ending Dec 2023: revenue —, net income $-31M—FY23Fiscal year ending Dec 2024: revenue —, net income $-57M—FY24Fiscal year ending Dec 2025: revenue —, net income $-84M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-58M$-84M—
Dec 2024——$-57M$-57M—
Dec 2023——$-35M$-31M—
Dec 2022——$-52M$-52M—
Dec 2021——$-90M$-90M—
Dec 2020——$-79M$-77M—
Dec 2019——$-39M$-37M—
Dec 2018——$-12M$-12M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-41M$0M$-42M$-1.68—
Dec 2024$-32M$0M$-32M$-1.31—
Dec 2023$-18M$0M$-18M$-0.84—
Dec 2022$-44M$0M$-44M$-1.54—
Dec 2021$-63M$0M$-63M$-3.03—
Dec 2020$-51M$0M$-51M$-2.63—
Dec 2019$-33M$0M$-33M$-1.94—
Dec 2018$-12M$0M$-12M$-3.71—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-12M—Dec ’24Three months to Mar 2025: revenue —, net income $-15M—Mar ’25Three months to Jun 2025: revenue —, net income $-16M—Jun ’25Three months to Sep 2025: revenue —, net income $-13M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-39M—Dec ’25Three months to Mar 2026: revenue —, net income $36M—Mar ’26Three months to Jun 2026: revenue —, net income $-75M—Jun ’26Three months to Sep 2026: revenue —, net income $-28M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-28M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of IRulya Therapeutics Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-58 M
Net income
$-84 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$94 M
Total liabilities
$129 M
Total equity
$-36 M

As of December-2025

Top 33 institutional investors in IRulya Therapeutics Inc.#

As of Sep 30, 2026
33 institutions held 2.2 M shares (about 20.5% of the shares outstanding) on Sep 30, 2026. The ten largest hold 20.2%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in IRulya Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Janus Henderson Group Ltd.1,714,957—15.82%$53 MNov 16, 2026
2Ikarian Capital, LLC95,652+23,401 (+32.39%)0.88%$3 MNov 16, 2026
3Squadron Capital Management LLC90,000+49,625 (+122.91%)0.83%$3 MNov 16, 2026
4Millennium Management LLC72,254+1,475 (+2.08%)0.67%$2 MNov 16, 2026
5Balyasny Asset Management L.P.69,970+3 (0.00%)0.65%$2 MNov 16, 2026
6Acuta Capital Partners, LLC52,918New0.49%$2 MNov 16, 2026
7Birchview Capital, LP40,601New0.37%$1 MNov 13, 2026
8Boothbay Fund Management, LLC21,291+7,380 (+53.05%)0.20%$1 MNov 16, 2026
9Jane Street Group, LLC20,156+7,514 (+59.44%)0.19%$1 MNov 12, 2026
10Seven Fleet Capital Management LP11,989New0.11%$0 MNov 16, 2026
11Geode Capital Management, LLC9,741New0.09%$0 MNov 6, 2026
12Vanguard Capital Management LLC9,216-2,828 (-23.48%)0.09%$0 MNov 13, 2026
13Cormorant Asset Management, LP5,4980 (0.00%)0.05%$0 MNov 16, 2026
14Vanguard Fiduciary Trust Co5,372+1,758 (+48.64%)0.05%$0 MNov 13, 2026
15BlackRock, Inc.1,689-13 (-0.76%)0.02%$0 MNov 13, 2026
16Morgan Stanley794-3,290 (-80.56%)0.01%$0 MNov 13, 2026
17Jpmorgan Chase & Co792+790 (+39500.00%)0.01%$0 MNov 12, 2026
18Wells Fargo & Company/mn314+304 (+3040.00%)0.00%$0 MNov 16, 2026
19Group One Trading LLC234New0.00%$0 MNov 10, 2026
20Gen-Wealth Partners Inc166+1 (+0.61%)0.00%$0 MNov 4, 2026
21Fortitude Family Office, LLC41+1 (+2.50%)0.00%$0 MOct 14, 2026
22BFC Planning, Inc.15+1 (+7.14%)0.00%$0 MNov 13, 2026
23BNP Paribas Financial Markets9New0.00%$0 MNov 12, 2026
24Allworth Financial LP80 (0.00%)0.00%$0 MNov 17, 2026
25Parallel Advisors, LLC6+3 (+100.00%)0.00%$0 MNov 3, 2026
Show all 33: investors 26 to 33
Institutional investors 26 to 33 in IRulya Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26UBS Group AG4-4,726 (-99.92%)0.00%$0 MNov 10, 2026
27Osaic Holdings, Inc.2New0.00%$0 MNov 12, 2026
28JDM Financial Group LLC2+1 (+100.00%)0.00%$0 MNov 17, 2026
29FMR LLC1New0.00%$0 MNov 10, 2026
30Jones Financial Companies Lllp1New0.00%$0 MNov 13, 2026
31Royal Bank Of Canada10 (0.00%)0.00%$0 MNov 16, 2026
32Westside Investment Management, Inc.10 (0.00%)0.00%$0 MNov 2, 2026
33Steward Partners Investment Advisory, LLC10 (0.00%)0.00%$0 MNov 13, 2026

Mutual funds holding IRulya Therapeutics Inc.#

1 funds hold shares worth $0 M (about 1.2% of the company). Since their previous reports 1 added shares and 0 sold, buying $0 M net.
Mutual funds holding IRulya Therapeutics Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.12,044$0 M1.2%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 1 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at IRulya Therapeutics Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$174 K
1 sale, 1 insider
Net, 12 months
-$174 K
open market only
Insiders on file
24
since
$163 K-$174 K$0Nov 2023: bought $27 K (2 trades), sold $0 (0 trades)Nov 23Dec 2023: bought $141 K (8 trades), sold $0 (0 trades)DecAug 2024: bought $163 K (9 trades), sold $0 (0 trades)AugDec 2025: bought $0 (0 trades), sold $174 K (1 trades)Dec
Bought (open market)Sold (open market)Hover a month for the totals
IRulya Therapeutics Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed John MilitelloChief Financial OfficerGrant or award+80,000——80,000Form 4
filed Luca BenattiDirectorSell-50,000$3.470$174 K39,179Form 4
filed Dirk ThyeCEO and CMO, DirectorGift-739,885——255,000Form 4
filed Dirk ThyeCEO and CMO, DirectorGiftindirect+739,885——739,885Form 4
filed Brendan HannahCBO, COO & CCOOption exercise+2,271$0.550$1 K336,547Form 4
filed Brendan HannahCBO, COO & CCOOption exercise+25,280$0.940$24 K361,827Form 4
filed Charles S. RyanPresidentGrant or award+7,548$1.200$9 K130,009Form 4
filed Brendan HannahCBO, COO & CCOGrant or award+37,736$1.200$45 K334,276Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: IRulya Therapeutics Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
127,816
45.8% of shares · 1.13 days to cover

Stock splits: 1-for-2.72 reverse split

Fails to deliver

  • : 969 shares at $31.62
  • : 236 shares at $31.38
  • : 660 shares at $33.08
  • : 302 shares at $32.83
  • : 1,844 shares at $34.68

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

IRulya Therapeutics Inc. scorecard#

Passes 1 of the 12 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 4). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-12.2%Free cash flow is -12.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.68 vs -1.31Diluted EPS -1.68 in fiscal 2025 against -1.31 the year before (report's currency).
    • ✗Net income higher than five years earlier-$84 M-$84 M in fiscal 2025 against -$77 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$84 MNet income -$84 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✗Short-term assets cover short-term liabilities0.5×Current ratio 0.53 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $6 M at the end of fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year15.8%Diluted shares up 15.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

IRulya Therapeutics Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

IRulya Therapeutics Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018
Income statement
Research and development35199.42561613010
General and administrative1518182630189.02.0
Operating expenses5857355290793912
Operating income−58−57−35−52−90−79−39−12
Interest and finance income1.22.93.51.10.62.02.20.8
Interest expense and finance costs———————1.0
Other non-operating income (expense)0.5−0.7−0.1−1.0−0.200—
Income before tax−81−57−32−52−90−77−37—
Income tax3.20.1−0.2r−0.30000
Net income including minority interests—−57−31−52−90−77−37−12
Net income attributable to shareholders−84−57−31−52−90−77−37−12
Earnings per share, basic-1.68-1.31-0.84-1.54-3.03-2.63-1.94-3.71
Earnings per share, diluted-1.68-1.31-0.84-1.54-3.03-2.63-1.94-3.71
Shares, weighted average (basic)5043373330———
Shares, weighted average (diluted)504337333029193.4
Balance sheet
Cash and cash equivalents5.86.2214129675125
Short-term investments1235544637674947
Receivables———0————
Other current assets0.10.10.10.30.40.70.70.1
Current assets2344779411213810673
Property, plant and equipment0.60.30.20.40.30.40.70.3
Right-of-use (leased) assets0.50.50.40.31.20.70.6—
Goodwill—01800———
Other intangible assets6860645.90———
Investments in associates0.10.10.1—————
Total assets9411416810413318912473
Accounts payable2.22.92.00.64.93.63.10.5
Debt due within a year180——————
Current liabilities437.39.63.114178.91.5
Lease liabilities (non-current)0.30.40.300.40.2——
Total liabilities12984833.315178.91.5
Retained earnings−460−376−320−288−237−147−70−33
Shareholders' equity−363085101119172115−33
Total liabilities and equity9411416810413318912473
Shares outstanding0.3r4443363030273.4
Cash-flow statement
Depreciation and amortization0.10.20.30.20.30.30.20.1
Share-based compensation5.14.75.21730142.10.2
Cash from operating activities−41−32−18−44−63−51−33−12
Capital expenditure−0.4−0.3−0.2−0.1−0.2−0.1−0.1−0.2
Cash from investing activities2322−5.81859−52−18−47
Shares issued——00.60———
Cash from financing activities18−4.80.10.76.81197776
Exchange-rate effect on cash−0.10.20.10.20.100—
Change in cash−0.4−15−24−252.91626—
Report10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at IRulya Therapeutics Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.4 M
Dr. Thye
Other top executives, average
$1.2 M
the CEO earned 2.1× this
$100 invested is now
$526
IRulya Therapeutics Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Dr. Thye$2.4 M$3.9 M$1.2 M$526
2024Dr. Thye$2.7 M$3.4 M$1.1 M$293
2023Dr. Thye$1.3 M$2.5 M$1.0 M$165

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at IRulya Therapeutics Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Acquisition or sale completed 2 · Directors and officers 9 · Material agreement 3 · Agreement ended 1 · New debt 1 · Unregistered share sale 2 · Shareholder rights changed 3 · Bylaws or fiscal year changed 5 · Shareholder vote 3 · Results announced 4

IRulya Therapeutics Inc.: events reported to the SEC
FiledWhat happenedFiling
Directors and officersBylaws or fiscal year changed8-K
Directors and officersBylaws or fiscal year changedShareholder vote8-K
Directors and officers8-K
Acquisition or sale completedDirectors and officers8-K
Delisting notice8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Shareholder rights changed8-K/A
Shareholder vote8-K
Acquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleBylaws or fiscal year changed8-K
Directors and officers8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Agreement ended8-K
Delisting notice8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Material agreementNew debt8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Shareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Oct 9, 2026

Acquisitions and funding#

1 acquisitions · 2 private funding rounds before listing

Businesses it acquired

Acquisitions by IRulya Therapeutics Inc.
AcquiredAcquisition dateCompletionPriceStakeSource
Ery DelOct 2023Oct 2023——Annual report

Private share sales · funding history

Private share sales of IRulya Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2026$115 MPrivate placement after listing$50 to $250 million27equity, optionsSEC
Jun 2025$11 MPrivate placement after listing$10 to $50 million15equity, optionsSEC
May 2018$84 MNo. 2$50 to $250 million36equitySEC
Dec 2015$8 MNo. 1$2 to $10 million13equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at IRulya Therapeutics Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2022–2023
Latest
—
2023-01-24
IRulya Therapeutics Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2023············—
2022············—
IRulya Therapeutics Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
47% of workforceRestructuring planSEC 8-K“Under the Plan, the Company is reducing headcount by approximately 47% through a reduction in its workforce.”Filing
36% of workforceRestructuring planSEC 8-K“The Company is further reducing headcount by 36%, bringing the total reduction to 67% from the January 2022 headcount levels.”Filing
53% of workforceRestructuring planSEC 8-K“Under the Plan, the Company is reducing headcount by approximately 53% through a reduction in its workforce.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How IRulya Therapeutics Inc. compares in Biotechnology

  • Market cap$343 M · higher than 53% of 726
  • FCF yield-12.2% · higher than 53% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
IRulya Therapeutics Inc.🇺🇸$343 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on 2021
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at IRulya Therapeutics Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show IRulya Therapeutics Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about IRulya Therapeutics Inc.? Suggest a correction